AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00267293
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given for fever control 15mg/kg
Trial: NCT00267293
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given for fever control 10 mg/kg
Trial: NCT02934269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01269788
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg , oral , daily 30 mins before breakfast, for 6 weeks
Trial: NCT01269788
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral , daily 30 mins before breakfast, for 6 weeks
Trial: NCT04382157
Drug: Mablet 360 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-released magnesium hydroxide
Trial: NCT01850303
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of carboplatin-paclitaxel
Trial: NCT00878449
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Trial: NCT03364985
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 tablets
Trial: NCT03364985
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets
Trial: NCT04699643
Drug: EVER4010001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please refer to information in arm/group descriptions.
Trial: NCT02420899
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/d or 20mg/d,po
Trial: NCT00459082
Drug: Dexmedetomine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01168882
Drug: RGB-286638
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
Trial: NCT01682473
Drug: ZSTK474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two arms, each with serial cohorts receiving escalating doses.
Trial: NCT00637442
Drug: Reminyl retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
Trial: NCT02174900
Drug: Artemether-Lumefantrine (AL) combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02315443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00404586
Drug: GW784568X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
Trial: NCT00404586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to GW784568X as aqueous nasal spray.
Trial: NCT03292783
Drug: NOV1501 (ABL001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF/DLL4 targeting bispecific antibody
Trial: NCT00781820
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
Trial: NCT04304781
Drug: KSP/QRH dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, ≥95% purity. Stored at \<20°C. Dark green, lyophilized powder in single-use amber vials.
Trial: NCT04687813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a tablet with the same appearance as FTP-198
Trial: NCT04010539
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
Trial: NCT00249288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken as 2, 1mg capsule daily for 12 weeks
Trial: NCT02431247
Drug: DRV/COBI FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
Trial: NCT02431247
Drug: FTC/TDF FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
Trial: NCT02431247
Drug: D/C/F/TAF FDC - Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of D/C/F/TAF FDC will be administered once daily.
Trial: NCT02112422
Drug: Intervention
RxNorm normalized name: DRESSING,QUIKCLOT INTERVENTION 1.5X1.5IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
Trial: NCT02431247
Drug: FTC/TDF FDC Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of FTC/TDF FDC will be administered once daily.
Trial: NCT02431247
Drug: DRV/COBI FDC Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo of DRV/COBI FDC will be administered once daily.
Trial: NCT04464564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT03550794
Drug: Thiamine Hydrochloride
RxNorm normalized name: Thiamine Hydrochloride
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
Trial: NCT03550794
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50ml of 0.9% NACL will serve as the placebo
Trial: NCT04630366
Drug: NST-1024
RxNorm normalized name: GLOVE NITRILE SM PFREE NSTERL TX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NST-1024
Trial: NCT04630366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to NST-1024
Trial: NCT03060031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
Trial: NCT02609997
Drug: proparacaine
RxNorm normalized name: proparacaine
DrugBank: Proparacaine (DB00807)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% proparacaine (Alcaine, Alcon Laboratories)
Trial: NCT01884116
Drug: NSAID patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01884116
Drug: NSAID patch + heating pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
Trial: NCT03354156
Drug: statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
Trial: NCT00283686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
Trial: NCT00457964
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 and 10 mg/day or 30, 50, 70mg/week
Trial: NCT04034199
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
Trial: NCT03001011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT00990028
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg oral, for 10 days
Trial: NCT00990028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg vehicle
Trial: NCT00575328
Drug: Maca Root
RxNorm normalized name: maca root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g/day of Maca Root for 12 weeks.
Trial: NCT05999942
Drug: Liposomal Amikacin for Inhalation
RxNorm normalized name: amikacin liposomal Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via the Pari LC STAR™ nebulizer.
Trial: NCT00575328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo provided by research pharmacy daily for 12 weeks.
Trial: NCT01493726
Drug: ALKS 9072, Low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection, given monthly
Trial: NCT01493726
Drug: ALKS 9072, High dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM injection, given monthly
Trial: NCT01493726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed matched placebo IM injection, given monthly
Trial: NCT02383589
Drug: Mycophenolate Mofetil Placebo
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MMF matching placebo will be administered orally Q12H.
Trial: NCT00376584
Drug: MK-0524A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04726007
Drug: Antithrombotic Agents
RxNorm normalized name: ANTITHROMBOTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic agents include anticoagulants, antiplatelet drugs, thrombolytic drugs.
Trial: NCT00591825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01030367
Drug: PETN, ISDN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
Trial: NCT02070471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02070471
Drug: LC28-0126 Dose A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC28-0126 Dose A
Trial: NCT02070471
Drug: LC28-0126 Dose B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC28-0126 Dose B
Trial: NCT03523000
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml continuous infusion at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
Trial: NCT03523000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
Trial: NCT01802489
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01802489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule identical in appearance to Amiloride 10mg capsule
Trial: NCT00186264
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00450775
Drug: Dermatix Q
RxNorm normalized name: Chew Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermatix Q applied twice daily
Trial: NCT01469988
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
Trial: NCT00003985
Drug: KRN7000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03472833
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
Trial: NCT02600598
Drug: LEO 43204 Gel, 0.037%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02122510
Drug: Bupivacine group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
Trial: NCT04322968
Drug: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were randomized into 4 treatment groups: chronic pain subjects treated with ketorolac, chronic pain subjects treated with ketamine, chronic pain+PTSD subjects treated with ketorolac, and chronic pain+PTSD subjects treated with ketamine.
Trial: NCT02755545
Drug: Product A
RxNorm normalized name: Vaccine product against severe acute respiratory syndrome coronavirus 2 (medicinal product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product A applied topically to the entire face or other affected area of the skin once daily
Trial: NCT02755545
Drug: Product B
RxNorm normalized name: Product base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product B applied topically to affected area of the skin 1 to 3 times daily
Trial: NCT02815774
Drug: SP2086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all subjects were given SP2086 50mg only one time.
Trial: NCT01716754
Drug: QGE031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 was supplied as 120 mg liquid in vial per 1 mL
Trial: NCT01716754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
Trial: NCT01389856
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
Trial: NCT03640312
Drug: QUARTET LDQT
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
Trial: NCT00206219
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03167177
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03167177
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Trial: NCT03167177
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Trial: NCT02716246
Drug: Prophylactic Immunomodulatory (IM) Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02716246
Drug: Optimized Prophylactic IM Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02716246
Drug: Adjuvant IM Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.
Trial: NCT01918722
Drug: ICH-1(herbal medicine with Hirudo, Tabanus)
RxNorm normalized name: TABANUS NIGROVITTATUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
Trial: NCT01918722
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo herbal medicine, one dose,bid, for 10 days
Trial: NCT01918722
Drug: ICH-2(herbal medicine without Hirudo, Tabanus)
RxNorm normalized name: TABANUS NIGROVITTATUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
Trial: NCT00076024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg twice daily \[bid\] continuous dosing
Trial: NCT02593734
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral drug therapy for depression
Trial: NCT00902161
Drug: MK0893
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MK0893 1000 mg (ten 100 mg tablets)
Trial: NCT00902161
Drug: MK0893-matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo to MK0893 (ten tablets)
Trial: NCT00301821
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00301821
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00195871
Drug: Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: coventional dosages
Trial: NCT02931591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00121836
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
Trial: NCT03447184
Drug: Androgen priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor
Trial: NCT02172170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00048711
Drug: N-acetylgalactosamine 4-sulfatase
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01386112
Drug: EUR-1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active oral medication
Trial: NCT01386112
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01545843
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-40 mg fluoxetine daily for 8 weeks
Trial: NCT04997590
Drug: Staphylococcal Enterotoxin C
RxNorm normalized name: Staphylococcal enterotoxin C specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
Trial: NCT00024050
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00024050
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01178320
Drug: Simvastatin, simvastatin plus extended-release niacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
Trial: NCT03099499
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
Trial: NCT00280501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02793011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
Trial: NCT00005863
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00075673
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.